

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Natural Beauty Bio-Technology Limited**

**自然美生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 00157)**

**APPOINTMENT OF AUDITORS  
APPOINTMENT OF INTERNAL CONTROL CONSULTANT AND  
FURTHER DELAY IN DESPATCH OF CIRCULAR**

Reference is made to (i) the announcements of the Company dated 14 August 2020 and 16 August 2020 (the “**Appointment Announcement**”) in relation to the appointment of the auditors of the Company; (ii) the announcement of the Company dated 24 March 2020 in relation to, amongst others, an investigation on certain audit findings raised by the Company’s then auditors (the “**Forensic Review**”); (iii) the announcement of the Company dated 25 March 2020 in relation to the suspension of trading in the shares of the Company (the “**Shares**”); (iv) the announcement of the Company dated 21 May 2020 in relation to the conditions for the resumption of trading in the Shares (the “**Resumption Guidance**”); (v) the announcement of the Company dated 21 July 2020 in relation to key findings of the Forensic Review (the “**Announcement**”); (vi) the announcement of the Company dated 14 August 2020 in relation to the additional condition for the resumption of trading in the Shares (the “**Additional Resumption Guidance Announcement**”); (vii) the announcement of the Company dated 23 July 2020 in relation to the Supplemental Agreements, 2020 CCT Agreement and the Transfer of Spa Business Agreement; and (viii) the announcement of the Company dated 12 August 2020 in relation to delay in despatch of circular in respect of the Supplemental Agreements, 2020 CCT Agreement and the Transfer of Spa Business Agreement (the “**Delay Announcement**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

## **APPOINTMENT OF AUDITORS**

As disclosed in the Appointment Announcement, the Board has resolved to appoint RSM Hong Kong as the auditors of the Company to fill the casual vacancy following the resignation of Deloitte as auditors of the Company, and to hold office until the conclusion of the next annual general meeting of the Company.

The Board is pleased to announce that RSM Hong Kong's client acceptance procedures as stated in the Appointment Announcement have been satisfactorily completed and are now officially appointed as the auditors of the Company with effect from 25 August 2020. RSM Hong Kong will commence audits works on the consolidated financial statements of the Group for the year ending 31 December 2019 ("**2019 Financial Statements**"). The Board will make further announcement(s) in respect of the progress of the audit process of the 2019 Financial Statements in due course.

## **APPOINTMENT OF INTERNAL CONTROL CONSULTANT**

As one of the conditions for resumption of trading of shares stated in the Additional Resumption Guidance Announcement, the Company should conduct an independent internal control review and demonstrate that the Company has in place adequate internal control and procedures that address the concerns identified in the Forensic Review referred to in the Announcement and ensure the Company to comply with the Listing Rules.

To assist the Company in fulfilling this condition, the Board is pleased to announce that the Company has engaged SHINEWING Risk Services Limited ("**Shinewing**") as its internal control consultant to conduct a review of the internal control systems and procedures of the Group in response to the concerns identified in the Forensic Review referred to in the Announcement (the "**Internal Control Review**"), and to make recommendations accordingly. Such appointment remains subject to Shinewing's client acceptance procedures before becoming effective. Based on the Board's assessment on the scope of work and the working timetable proposed by Shinewing, it is currently expected that a draft report of the results of the Internal Control Review will be ready by end of November 2020, and the final report should be ready as soon as practicable thereafter.

The Company will keep the Shareholders and its potential investors informed if there is any material change to the expected timetable disclosed above and the results of the Internal Control Review by way of announcement(s).

## **FURTHER DELAY IN DESPATCH OF CIRCULAR**

As stated in the Delay Announcement, a circular (the “**Circular**”) containing, among other things, further details of the Supplemental Agreements, the 2020 CCT Agreements and Transfer of Spa Business Agreement, the respective advice of the Independent Financial Adviser and the Independent Board Committee and the notice of the EGM was expected to be despatched to the Shareholders on or before 26 August 2020. As additional time is required for the Company to prepare and finalise certain information to be included in the Circular, it is expected that the date of despatch of the Circular and the notice of the EGM will be further postponed to a date falling on or before 9 September 2020.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the Shares on the Stock Exchange has been suspended at the request of the Company since 9:00 a.m. on 25 March 2020 and will remain suspended until further notice. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board  
**Natural Beauty Bio-Technology Limited**  
**LEI Chien**  
*Chairperson*

Hong Kong, 25 August 2020

*As at the date of this announcement, the Board comprises Dr. Lei Chien and Mr. Pan Yi-Fan as executive directors; Ms. Lu Yu-Min, Ms. Lin Shu-Hua and Mr. Chen Shou-Huang as non-executive directors; and Mr. Chen Ruey-Long, Mr. Lu Chi-Chant and Mr. Yang Shih-Chien as independent non-executive directors.*